Oncolytic competition

One of the reasons companies want to move rapidly through the clinic is that competitors often are chasing them with improved second generation products. Whether this is the case with Onyx Pharmaceuticals Inc.'s ONYX-015 oncolytic adenovirus versus Schering-Plough Corp.'s new strain of oncolytic adenovirus, 01/PEME, only time and clinical testing

Read the full 504 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers